BCLI
BRAINSTORM CELL THERAPEUTICS INC.
Next earnings Aug 12, 2026 · consensus $-0.30 EPS
Last earnings +0.0% on 2026-05-15
$0.93
▲ 0.00%$0.93▼ -23.77%
over 1Y
L $0.48EODHDH $1.31
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+3.3%
1M+34.8%
3M+3.3%
YTD+52.5%
1Y-23.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
High return on equity (103.2%).
BRAINSTORM CELL THERAPEUTICS INC. shows limited reported revenue, and 103.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$24.5M | -$24.8M | -$21.4M | -$11.7M | -$9.95M |
| Net income | -$24.5M | -$24.3M | -$17.2M | -$11.6M | -$10.3M |
| Diluted EPS | -$0.68 | -$0.66 | -$6.00 | -$2.31 | -$1.11 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$11.2M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-100.4%
FCF yield-68.1%
Quality & risk
ROIC (est.)—
Free cash flow-$6.99M
Total debt$967K
Net cash-$938K
Piotroski F-Score1/6
Capital returns
Buyback yield1.1%
Dividend yield (est.)—
Shareholder yield1.1%
Shares Δ YoY+69.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗3Period ending 2026-05-252026-06-03open ↗EFFECTFiling2026-06-02open ↗4Period ending 2026-02-262026-05-29open ↗4Period ending 2026-02-262026-05-29open ↗4Period ending 2026-02-262026-05-29open ↗4Period ending 2026-02-262026-05-29open ↗4Period ending 2026-02-262026-05-29open ↗8-KPeriod ending 2026-05-252026-05-28open ↗S-8Filing2026-05-21open ↗S-1Filing2026-05-21open ↗4Period ending 2026-02-262026-05-20open ↗4Period ending 2026-02-262026-05-20open ↗
Frequently asked
- Is BRAINSTORM CELL THERAPEUTICS INC. (BCLI) a buy?
- BCLI currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (103.2%).
- What is BRAINSTORM CELL THERAPEUTICS INC.'s quality score?
- BCLI scores 45/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001137883, latest 10-Q filed 2026-05-15) · EODHD · as of 6/22/2026, 11:32:11 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.